Use of Pulmonary Inhalants Remains Remarkably High After Atrial Septal Defect Closure

Circ J. 2018 Oct 25;82(11):2913-2916. doi: 10.1253/circj.CJ-18-0613. Epub 2018 Oct 6.

Abstract

Background: Post-repair atrial septal defects (ASD) patients are frequently discharged from follow-up, but the extent of pulmonary symptoms long-term post-repair is unknown. Methods and Results: The national CONgenital CORvitia registry was linked to the national Drug Registry to investigate all ambulatory-dispensed pulmonary inhalants for 2006-2014. ASD patients were compared with age- and sex-matched referents from the general population. A total of 1,959 adult patients (age 42±17 years; 66% female; 1,223 [62%] repaired) were included. Compared with the referents, ASD patients had more inhalant use, even at long-term post-repair follow-up (OR=1.81 [95% CI 1.62-2.03]; P<0.001).

Conclusions: ASD patients had 2-fold higher inhalant use compared with referents even at long-term post-repair follow-up, suggesting persistent pulmonary functional impairment.

Keywords: Adult congenital heart disease; Atrial septal defects; Dyspnea; Pulmonary inhalants.

Publication types

  • Comparative Study
  • Multicenter Study

MeSH terms

  • Administration, Inhalation
  • Adult
  • Female
  • Follow-Up Studies
  • Heart Septal Defects* / complications
  • Heart Septal Defects* / surgery
  • Humans
  • Lung Diseases* / complications
  • Lung Diseases* / drug therapy
  • Lung*
  • Male
  • Middle Aged
  • Registries*